BioStock article: Aptahem’s CEO on clinical studies in 2022
When sepsis company Aptahem recently received its European patent and thus strengthened the protection for the drug candidate Apta-1 in eleven European countries, it was the culmination of a news-intensive 2021. Aptahem’s CEO Mikael Lindstam will soon be able to note the preclinical program as completed with the intention of starting the first human studies with Apta-1 in 2022. BioStock contacted Lindstam to get his thoughts on 2021 and hear his expectations for 2022.
Read the full interview with Mikael Lindstam at biostock.se.
For further information:
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.